A Milestone Clinical Study Reveals that Elevating Nicotinamide Adenine Dinucleotide (NAD+) with Nicotinamide Riboside (NR) Supplementation Effectively Reduces Inflammation in Both Healthy Subjects and Immune Cells Derived from Psoriasis Patients
LOS ANGELES--(BUSINESS WIRE)--ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, announced the U.S. Patent & Trademark Office’s Patent Trial and Appeal Board’s (“PTAB”) decision to reject Thorne Research, Inc. attempt to invalidate U.S. Patent No. 8,197,807 (“the 807 patent”). ChromaDex holds an exclusive license to the 807 patent for compositions including nicotinamide riboside (NR) from the Trustees of Dartmouth College. The decision, if upheld upon appeal, precludes Thorne Research, Inc. from raising these arguments, or any other arguments they could have reasonably raised before the PTAB in the New York District Court lawsuit ChromaDex brought against Thorne Research, Inc. wherein ChromaDex alleges Thorne Research, Inc. is infringing the 807 patent.
LOS ANGELES--(BUSINESS WIRE)--ChromaDex Corp. (NASDAQ:CDXC) today announced promising findings from a first-of-its-kind clinical study, as reported in the peer-reviewed journal Cell Metabolism by a team of scientists led by Prof. Charalampos Tzoulis, Haukeland University Hospital and University of Bergen, in Norway. The clinical trial was part of the ChromaDex External Research Program (CERP™) and investigated the company’s proprietary Niagen® ingredient (patented nicotinamide riboside, or “NR”) in patients with Parkinson’s disease (PD). Results of the phase I clinical trial showed that NR supplementation significantly increased cerebral nicotinamide adenine dinucleotide (NAD) levels, and resulted in altered cerebral energy metabolism and decreased levels of inflammatory cytokines in patients with PD. This clinical study is a milestone in NR and PD research and builds upon previous preclinical studies exploring the positive impact of NR on neurodegenerative diseases.
LOS ANGELES--(BUSINESS WIRE)--ChromaDex Corp. (NASDAQ:CDXC) today announced results of the 18th clinical trial on its flagship Niagen® (patented nicotinamide riboside, or “NR”) ingredient with promising, peer-reviewed findings reported in the Journal of Clinical Investigation. The study investigated the anti-inflammatory effects of ChromaDex’s proprietary NR ingredient in monocytes (a type of white blood cell) extracted from two groups: young, healthy subjects and patients diagnosed with systemic lupus erythematosus (SLE). The study was conducted as part of the ChromaDex External Research Program (CERP™) and adds to a growing body of clinical evidence supporting the potential anti-inflammatory effects of NR supplementation.
LOS ANGELES--(BUSINESS WIRE)--ChromaDex Corp. (NASDAQ:CDXC) today announced a supply agreement with Designs for Health, a U.S.-based manufacturer of premium dietary supplements for healthcare practitioners (HCPs). ChromaDex’s proprietary healthy aging ingredient Niagen®, the world’s first and only FDA-safety reviewed and patented form of nicotinamide riboside, will be added to multi-ingredient Designs for Health formulas. The new products will be available exclusively through the company’s extensive healthcare practitioner (HCP) network.
LOS ANGELES--(BUSINESS WIRE)--ChromaDex Corp. (NASDAQ:CDXC) today announced findings from recently published preclinical studies, as well as recently registered clinical research, investigating Niagen® (patented nicotinamide riboside, or “NR”) in various health outcomes. Through the industry-leading ChromaDex External Research Program (CERP™), ChromaDex supplies Niagen® to researchers around the world at no cost to help advance the understanding of NR’s impact on various age-related health conditions.
LOS ANGELES--(BUSINESS WIRE)-- ChromaDex Corp. (NASDAQ:CDXC) today highlighted a new study from Nature Immunology that found nicotinamide riboside (NR) helped energize tumor infiltrating T-cells (TILs) in samples extracted from mice. In a preclinical mouse model, NR was shown to improve T-cell function, which is a component of new cancer immunotherapies such as PD-1 and PDL-1 inhibitors. These findings lend further data to the potential role of NR in supporting healthy mitochondrial function.
DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations, today announced a partnership with Invitae, a leading medical genetics company, to support Invitae’s Detect Lysosomal Storage Diseases (Detect LSDs) and Behind the Seizure® programs. The Detect LSDs program enables the rapid diagnosis of lysosomal storage disorders (LSDs), including GM2 gangliosidosis (also known as Tay-Sachs and Sandhoff disease). The Behind the Seizure program is an innovative, cross-company collaboration that supports faster diagnosis for children with epilepsy. The Behind the Seizure program will also support patient identification across Taysha’s broad pipeline of gene therapies for which a number of indications have an underlying seizure phenotype.
LOS ANGELES, Dec. 11, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) today announced the launch of Tru Niagen® Pro 500, the largest daily serving of its patented nicotinamide riboside (NR, or Niagen®) ingredient in the world. The product will be available exclusively through licensed healthcare practitioners in the United States, launching this weekend at the American Academy for Anti-Aging Medicine (A4M) Annual Meeting in Las Vegas, NV.
LOS ANGELES, Oct. 17, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today that the results of a preclinical study conducted by Nestlé were published last month in the journal Nature Communications, a peer-reviewed open access scientific journal published by the Nature Publishing Group. The study investigated the impact on the liver when its cells lose the ability to use the nutrient nicotinamide riboside (NR). The preclinical study concluded that the tissue’s natural ability to utilize NR is important for maintaining resilience during periods of metabolic stress such as a high-fat diet. It is also the first study to show the physiological consequences that arise when cells lose the ability to use NR.